Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome - Tabular View

Tracking Information
First Received Date ^ICMJE	February 19, 2008
Last Updated Date	February 19, 2008
Start Date ^ICMJE	November 1994
Primary Completion Date	October 1996 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE (submitted: February 19, 2008)	Bone Mineral Density in columna lumbalis, collum femoris and distal ulnae Bone mineral density (BMD; grams/ square centimetre) were measured at lumbar spine, hip and the non-dominant forearm. [ Time Frame: Evey 5 years ] [ Designated as safety issue: No ]
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	No Changes Posted
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome
Official Title ^ICMJE	Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome
Brief Summary	Turner Syndrome (TS) is associated with osteopenia and osteoporosis. Reduced bone mineral density (BMD) and increased risk of fractures are present in many younger and middle-aged women with TS. The objective is therefore to describe longitudinal changes in BMD in TS. The study is an observational follow-up study. Examinations at baseline, after 5 and 10 years. Bone mineral density is measured by dual energy x-ray absorptiometry (DEXA) and bone turnover by bone markers. Main Outcome Measures: Bone mineral density (BMD; grams/ square centimetre) were measured at lumbar spine, hip and the non-dominant forearm.
Detailed Description
Study Phase
Study Type ^ICMJE	Observational
Study Design ^ICMJE	Cohort, Prospective
Condition ^ICMJE	Turner Syndrome
Intervention ^ICMJE
Study Arms / Comparison Groups	Women with Turner syndrome Healthy control women
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Active, not recruiting
Enrollment ^ICMJE	54
Estimated Completion Date	June 2010
Primary Completion Date	October 1996 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Turner syndrome verified by karyotyping Exclusion Criteria: untreated hypothyroidism or hyperthyroidism present or past malignant diseases clinical liver disease treatment with drugs known to interfere with bone metabolism (e.g. glucocorticoids)
Gender	Female
Ages	18 Years and older
Accepts Healthy Volunteers	Yes
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE

Administrative Information
NCT ID ^ICMJE	NCT00625001
Responsible Party	MD, Dr. Med. Sci Claus Gravholt, University of Aarhus
Study ID Numbers ^ICMJE	1994/2424
Study Sponsor ^ICMJE	University of Aarhus
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	University of Aarhus
Verification Date	February 2008
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP